Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25443837 | 0.94 | PKM (0.45) | GAAALOX15TSHRHSD17B10HRH3 | |
| SCHEMBL25075308 | 0.91 | HRH3 (0.40) | GAAALOX15TSHRHSD17B10HRH3 | |
| SCHEMBL26494147 | 0.91 | HRH3 (0.40) | GAAALOX15TSHRHSD17B10HRH3 | |
| SCHEMBL26494352 | 0.91 | HRH3 (0.40) | GAAALOX15TSHRHSD17B10HRH3 | |
| SCHEMBL24330246 | 0.89 | GAA (0.47) | GAAALOX15TSHRHSD17B10PKM | |
| SCHEMBL26494180 | 0.86 | GAA (0.42) | GAAALOX15TSHRHSD17B10HRH3 | |
| SCHEMBL26494077 | 0.85 | HRH3 (0.42) | HRH3KCNH2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL13004984 | 0.85 | GAA (0.55) | GAAALOX15TSHRHSD17B10HRH3 | |
| SCHEMBL26171349 | 0.83 | PIK3CD (0.51) | GAAALOX15TSHRHSD17B10CYP2D6 | |
| SCHEMBL27051351 | 0.83 | SIGMAR1 (0.40) | GAAALOX15TSHRHSD17B10HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | GAA 671/4885ALOX15 4003/4885TSHR 3035/4885 |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | GAA 2228/4885ALOX15 3836/4885TSHR 2649/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | GAA 1592/4885ALOX15 4703/4885TSHR 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.